News
ABBV
185.58
-1.33%
-2.51
FDA to speed up AI rollout to accelerate drug reviews
Seeking Alpha · 9h ago
Hartford Healthcare Fund Q1 2025 Commentary
Seeking Alpha · 10h ago
BeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New Profit
Seeking Alpha · 15h ago
TEVA Beats on Q1 Earnings, Expects $700M Cost Savings by 2027, Stock Up
NASDAQ · 17h ago
Franklin Global Allocation Fund Q1 2025 Commentary
Seeking Alpha · 18h ago
Stocks See Support as US-UK Trade Deal Bolsters Trade Optimism
Barchart · 18h ago
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) - June 3, 2025 Deadline to Join - Contact The Gross Law Firm
PR Newswire · 19h ago
Stocks Rally on UK Trade Deal and Chip Rule Change
Barchart · 19h ago
Marjorie Taylor Greene Goes Stock Shopping Again: Here Are 50+ Stocks The Congresswoman Bought
Benzinga · 1d ago
2024 Total Dividend Income And Portfolio Update
Seeking Alpha · 1d ago
This House of Representative Just Bought Up To $915K In AbbVie Stock
Benzinga · 1d ago
LLY, VRTX, or ABBV: Which Healthcare Stock Is the Best Pick?
TipRanks · 1d ago
Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street
The Wall Street Journal · 1d ago
Fidelity Select Health Care Portfolio Q1 2025 Commentary
Seeking Alpha · 1d ago
The Zacks Analyst Blog Highlights Johnson & Johnson and AbbVie
Barchart · 1d ago
Are Wall Street Analysts Predicting AbbVie Stock Will Climb or Sink?
Barchart · 1d ago
Stocks Retreat on Concerns About Economic Damage from Tariffs
NASDAQ · 2d ago
Putnam Large Cap Value Fund Q1 2025 Commentary
Seeking Alpha · 2d ago
ABBV Quantitative Stock Analysis
NASDAQ · 2d ago
AbbVie to Present at the Bank of America Securities Healthcare Conference
PR Newswire · 2d ago
More
Webull provides a variety of real-time ABBV stock news. You can receive the latest news about Abbvie Inc through multiple platforms. This information may help you make smarter investment decisions.
About ABBV
More
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.